Literature DB >> 25483534

The burden of disease of Herpes Zoster in Tuscany.

Miriam Levi1, Irene Bellini, Leonardo Capecchi, Luca Pieri, Angela Bechini, Sara Boccalini, Silvia Callaioli, Roberto Gasparini, Donatella Panatto, Emilia Tiscione, Paolo Bonanni.   

Abstract

Herpes zoster (HZ) is a disease caused by the reactivation of the latent α-herpes virus varicella zoster virus (VZV), for which, in Italy, a specific surveillance system does not exist, but around 200 000 cases are estimated each year. In older patients, who are at increased risk of developing HZ, symptoms are more severe and the chances to develop postherpetic neuralgia (PHN), the most severe complication, are substantially higher. A vaccine against HZ with demonstrated efficacy and an acceptable safety profile is now available and is recommended in Europe for adults >50 years.   In anticipation of the possible introduction of an immunization programme for the elderly in Tuscany, the burden of disease caused by HZ and its complications was assessed through a retrospective analysis of the hospital discharge records between 2002 and 2012, using the ICD-9-CM 053 code. In the period 2002-2012, 4475 hospital admissions were registered with annual means of 368 hospitalizations and 39 day-hospital admissions. Most of the hospitalizations (68%) involved subjects > 65 years; the mean length of stay was 9.5 days. Slightly more than half (51.2%) of total hospital admissions were complicated cases. The most frequent were neurological complications (24.2% of total admissions), followed by ophthalmic complications (16.5%). Cases with neurological complications were those with the higher average length of stay and higher average costs for case. This study confirmed the epidemiological impact of HZ and its complications and the positive impact on morbidity that the introduction of the HZ vaccination could have in older age groups.

Entities:  

Keywords:  Herpes zoster; Italy; Tuscany; epidemiology; hospital admissions; hospital discharge records

Mesh:

Year:  2014        PMID: 25483534      PMCID: PMC4514367          DOI: 10.4161/hv.35859

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  24 in total

1.  The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales.

Authors:  W J Edmunds; M Brisson; J D Rose
Journal:  Vaccine       Date:  2001-04-30       Impact factor: 3.641

2.  Acute pain in herpes zoster and its impact on health-related quality of life.

Authors:  Jennifer Katz; Edith M Cooper; Robert R Walther; Eugene W Sweeney; Robert H Dworkin
Journal:  Clin Infect Dis       Date:  2004-07-19       Impact factor: 9.079

Review 3.  Vaccination to prevent herpes zoster and postherpetic neuralgia.

Authors:  Michael N Oxman
Journal:  Hum Vaccin       Date:  2007-03-23

4.  Epidemiology of varicella zoster virus infection in Canada and the United Kingdom.

Authors:  M Brisson; W J Edmunds; B Law; N J Gay; R Walld; M Brownell; L L Roos; L Roos; G De Serres
Journal:  Epidemiol Infect       Date:  2001-10       Impact factor: 2.451

5.  Risk factors for postherpetic neuralgia in patients with herpes zoster.

Authors:  Beth F Jung; Robert W Johnson; David R J Griffin; Robert H Dworkin
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

6.  The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region.

Authors:  A Nardone; F de Ory; M Carton; D Cohen; P van Damme; I Davidkin; M C Rota; H de Melker; J Mossong; M Slacikova; A Tischer; N Andrews; G Berbers; G Gabutti; N Gay; L Jones; S Jokinen; G Kafatos; M V Martínez de Aragón; F Schneider; Z Smetana; B Vargova; R Vranckx; E Miller
Journal:  Vaccine       Date:  2007-08-08       Impact factor: 3.641

7.  Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom.

Authors:  A Gauthier; J Breuer; D Carrington; M Martin; V Rémy
Journal:  Epidemiol Infect       Date:  2008-05-09       Impact factor: 2.451

8.  Factors influencing the features of postherpetic neuralgia and outcome when treated with tricyclics.

Authors:  David Bowsher
Journal:  Eur J Pain       Date:  2003       Impact factor: 3.931

Review 9.  Herpes zoster associated hospital admissions in Italy: review of the hospital discharge forms.

Authors:  Giovanni Gabutti; Carlotta Serenelli; Alessandra Cavallaro; Pietro Ragni
Journal:  Int J Environ Res Public Health       Date:  2009-09-02       Impact factor: 3.390

10.  Risk of stroke following herpes zoster: a self-controlled case-series study.

Authors:  Sinéad M Langan; Caroline Minassian; Liam Smeeth; Sara L Thomas
Journal:  Clin Infect Dis       Date:  2014-04-02       Impact factor: 9.079

View more
  3 in total

1.  Immunogenicity and Safety of a Live Attenuated Zoster Vaccine (ZOSTAVAX™) in Korean Adults.

Authors:  Won Suk Choi; Jung-Hyun Choi; Jun Yong Choi; Joong Sik Eom; Sang Il Kim; Hyunjoo Pai; Kyong Ran Peck; Jang Wook Sohn; Hee Jin Cheong
Journal:  J Korean Med Sci       Date:  2015-12-24       Impact factor: 2.153

2.  Hospital-based herpes zoster diagnoses in Denmark: rate, patient characteristics, and all-cause mortality.

Authors:  Sigrun A J Schmidt; Johnny Kahlert; Mogens Vestergaard; Henrik C Schønheyder; Henrik T Sørensen
Journal:  BMC Infect Dis       Date:  2016-03-01       Impact factor: 3.090

3.  The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy.

Authors:  Sean Matthews; Antonio De Maria; Marco Passamonti; Giovanni Ristori; Idalba Loiacono; Anna Puggina; Desmond Curran
Journal:  Open Forum Infect Dis       Date:  2019-01-12       Impact factor: 3.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.